2025;2:101452 DOI: Received: August 10, 2025 Accepted: November 19, 2025 Published: December 18, 2025 Academic Editor: Charlotte Steenblock, University Clinic Carl Gustav Carus, Germany Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and dual incretin agonists have demonstrated significant potential in improving adipose tissue function beyond their established effects on appetite suppression and weight loss
This ensures continuous treatment and ongoing medical monitoring
Spinal cord repair: advances in biology and technology
Are you self-conscious about gaps in your smile
The night before, the two argued via text about his relationship with a woman
Semaglutide may not be suitable for individuals who: Are pregnant or breastfeeding Have a history of certain thyroid cancers Have certain endocrine conditions Have specific medical conditions identified by your provider What to Expect During Your Semaglutide Program Our semaglutide program at Plenitude Medical & Wellness Spa is designed to help you lose weight safely, comfortably, and effectively under medical supervision